FY2022 Q3 Financial and R&D Update

Status of Clinical Studies in Lung Cancer NSCLC SCLC 1L AGA DESTINY-Lung04 (HER2m) 2L+ HERTHENA-Lung01/02 (EGFRM) HER3-DXd EHHERTUⓇ DESTINY-Lung01/02 (HER2m) TROPION -Lung07 Non- AGA (PD-L1<50%) Dato-DXd +Pembro±Plat TROPION -Lung08 (PD-L1≥50%) Dato-DXd +Pembro Dato-DXd TROPION-Lung01 Monotherapy DS-7300 Daiichi-Sankyo HERTHENA-Lung01 FY2022 Q4: TLR anticipated TROPION-Lung01 FY2023 Q1: TLR anticipated TROPION-Lung07 Jan 2023: Study started Pivotal studies only, not exhaustive Planning study AGA: actionable genomic alteration, EGFRm: EGFR mutated, HER2m: HER2 mutant, NSCLC: non-small cell lung cancer, Pembro: pembrolizumab, Plat: platinum-based chemotherapy, SCLC: small cell lung cancer, TLR: top line results 27

View entire presentation